ACE2 and COVID-19: In COVID-19 patients, EC damage and activation responses are also likely to be exacerbated by impaired ACE2 activity that increases the severity of ARDS, AngII-directed EC damage, bradykinin-directed permeability and inflammation, and the loss of protective anti-inflammatory Ang1-7 responses (9, 24, 28, –, 30).